1-11 of 11
Thomas M. Cardillo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo

Ian Nessler, Baron Rubahamya, Anna Kopp, Scott Hofsess, Thomas M. Cardillo, Nalini Sathyanarayan, Jennifer Donnell, Serengulam V. Govindan, Greg M. Thurber
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (3): 343–353.
https://doi.org/10.1158/1535-7163.MCT-23-0437
Published: 04 March 2024
View article titled, Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses <em>In Vivo</em>
Open the PDF for Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release

Anna Kopp, Scott Hofsess, Thomas M. Cardillo, Serengulam V. Govindan, Jennifer Donnell, Greg M. Thurber
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (1): 102–111.
https://doi.org/10.1158/1535-7163.MCT-22-0375
Published: 03 January 2023
View article titled, Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release
Open the PDF for Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release in another window
Includes: Supplementary data
Journal Articles

Novel Peptide Camptothecin Drug-linkers for Potent ADCs—Letter

David M. Goldenberg, Robert M. Sharkey, Serengulam V. Govindan, Thomas M. Cardillo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (1): 237.
https://doi.org/10.1158/1535-7163.MCT-21-0212
Published: 07 January 2022
View article titled, Novel Peptide Camptothecin Drug-linkers for Potent ADCs—Letter
Open the PDF for Novel Peptide Camptothecin Drug-linkers for Potent ADCs—Letter in another window
Journal Articles

Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody–Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130)

Robert M. Sharkey, Serengulam V. Govindan, Thomas M. Cardillo, Jennifer Donnell, Jing Xia, Edmund A. Rossi, Chien-Hsing Chang, David M. Goldenberg
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1): 196–203.
https://doi.org/10.1158/1535-7163.MCT-17-0442
Published: 01 January 2018
View article titled, Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody–Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130)
Open the PDF for Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody–Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130) in another window
Includes: Supplementary data
Journal Articles

IMMU-140, a Novel SN-38 Antibody–Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma

Thomas M. Cardillo, Serengulam V. Govindan, Maria B. Zalath, Diane L. Rossi, Yang Wang, Chien-Hsing Chang, David M. Goldenberg
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (1): 150–160.
https://doi.org/10.1158/1535-7163.MCT-17-0354
Published: 01 January 2018
View article titled, IMMU-140, a Novel SN-38 Antibody–Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma
Open the PDF for IMMU-140, a Novel SN-38 Antibody–Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma in another window
Includes: Supplementary data
Journal Articles

Combining ABCG2 Inhibitors with IMMU-132, an Anti–Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers

Chien-Hsing Chang, Yang Wang, Maria Zalath, Donglin Liu, Thomas M. Cardillo, David M. Goldenberg
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (8): 1910–1919.
https://doi.org/10.1158/1535-7163.MCT-16-0219
Published: 03 August 2016
View article titled, Combining ABCG2 Inhibitors with IMMU-132, an Anti–Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers
Open the PDF for Combining ABCG2 Inhibitors with IMMU-132, an Anti–Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers in another window
Includes: Supplementary data
Journal Articles

Abstract C166: Combining an anti-Trop-2 antibody-SN-38 conjugate (sacituzumab govitecan) with microtubule inhibitors (paclitaxel and eribulin mesylate) or PARP inhibitor (olaparib) significantly improves therapeutic outcome in experimental triple-negative breast cancer (TNBC)

Thomas M. Cardillo, Serengulam V. Govindan, Maria Zalath, Roberto Arrojo, Robert M. Sharkey, David M. Goldenberg
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C166.
https://doi.org/10.1158/1535-7163.TARG-15-C166
Published: 01 December 2015
View article titled, Abstract C166: Combining an anti-Trop-2 antibody-SN-38 conjugate (sacituzumab govitecan) with microtubule inhibitors (paclitaxel and eribulin mesylate) or PARP inhibitor (olaparib) significantly improves therapeutic outcome in experimental triple-negative breast cancer (TNBC)
Journal Articles

Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon-α

Edmund A. Rossi, Diane L. Rossi, Thomas M. Cardillo, Chien-Hsing Chang, David M. Goldenberg
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (10): 2341–2351.
https://doi.org/10.1158/1535-7163.MCT-14-0345
Published: 02 October 2014
View article titled, Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon-α
Open the PDF for Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon-α in another window
Includes: Supplementary data
Journal Articles

Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers

Serengulam V. Govindan, Thomas M. Cardillo, Robert M. Sharkey, Fatma Tat, David V. Gold, David M. Goldenberg
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (6): 968–978.
https://doi.org/10.1158/1535-7163.MCT-12-1170
Published: 09 June 2013
View article titled, Milatuzumab–SN-38 Conjugates for the Treatment of CD74<sup>+</sup> Cancers
Open the PDF for Milatuzumab–SN-38 Conjugates for the Treatment of CD74<sup>+</sup> Cancers in another window
Includes: Supplementary data
Journal Articles

Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies

Robert M. Sharkey, Serengulam V. Govindan, Thomas M. Cardillo, David M. Goldenberg
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (1): 224–234.
https://doi.org/10.1158/1535-7163.MCT-11-0632
Published: 09 January 2012
View article titled, Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies
Open the PDF for Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies in another window
Includes: Supplementary data
Journal Articles

Ranpirnase (Frog RNase) Targeted with a Humanized, Internalizing, Anti–Trop-2 Antibody Has Potent Cytotoxicity against Diverse Epithelial Cancer Cells

Chien-Hsing Chang, Pankaj Gupta, Rosana Michel, Meiyu Loo, Yang Wang, Thomas M. Cardillo, David M. Goldenberg
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (8): 2276–2286.
https://doi.org/10.1158/1535-7163.MCT-10-0338
Published: 09 August 2010
View article titled, Ranpirnase (Frog RNase) Targeted with a Humanized, Internalizing, Anti–Trop-2 Antibody Has Potent Cytotoxicity against Diverse Epithelial Cancer Cells
Open the PDF for Ranpirnase (Frog RNase) Targeted with a Humanized, Internalizing, Anti–Trop-2 Antibody Has Potent Cytotoxicity against Diverse Epithelial Cancer Cells in another window
Includes: Supplementary data